FindTrial
Sign In

Understanding the clinical utility of dapagliflozin, sitagliptin and metformin fixed dose combination in Indian Diabetes patients

Evaluation of usage pattern and Tolerability of a fixed drug combination of dapagliflozin, sitagliptin and metformin in Indian Type 2 Diabetes Mellitus Patients: A Retrospective Cross-Sectional Study (TREAT-DM) - TREAT-DM

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/10/095641
Enrollment
35000
Registered
2025-10-06
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E11- Type 2 diabetes mellitus

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

Torrent Pharmaceuticals Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or female patient 2. 18 years and above 3. T2DM patients on triple drug therapy of Dapagliflozin + Sitagliptin + Metformin

Exclusion criteria

Exclusion criteria: 1. As per Drs decision based on the prescribing information

Design outcomes

Primary

MeasureTime frame
1. Proportion of patients initiated with fixed drug combination of dapagliflozin, sitagliptin and metformin extended-release tablets and its correlation with HbA1CTimepoint: Single time point—

Secondary

MeasureTime frame
1. Proportion of patients initiated with fixed drug combination of dapagliflozin, sitagliptin and metformin extended-release tablets and associated comorbidities 2. Proportion of patients initiated with fixed drug combination of dapagliflozin, sitagliptin and metformin extended-release tablets and its reason for prescription 3. Proportion of patients reporting adverse events with use of fixed drug combination of dapagliflozin, sitagliptin and metformin extended-release tabletsTimepoint: Single time point—

Countries

India

Contacts

Public ContactDr Mukesh Gabhane

Torrent Pharmaceuticals Ltd.

mukeshgabhane@torrentpharma.com7069000639

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026